Skip to main content
SpringerLink
Log in

Addition of interleukin-2in vitro augments detection of lymphokine-activated killer activity generatedin vivo

  • Original articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

Thein vivo administration of repetitive weekly cycles of interleukin-2 (IL-2) to patients with cancer enhances the ability of freshly obtained peripheral blood lymphocytes (PBL) to lyse both the natural-killer(NK)-susceptible K562 and the NK-resistant Daudi targets. Lysis of both targets is significantly augmented by inclusion of IL-2 in the medium during the cytotoxicity assay. This boost is much greater for cells obtained following thein vivo IL-2 therapy than for cells obtained prior to the initiation of therapy or for cells from healthy control donors. In addition to direct lytic activity, the PBL obtained followingin vivo IL-2 show a rapid increase in lymphokine-activated killer (LAK) activity with more prolongedin vitro IL-2 exposure, indicating that LAK effectors primedin vivo respond with “secondary-like” kinetics to subsequent IL-2in vitro. Lymphocytes from healthy control individuals, cultured in IL-2 under conditions attempting to simulate thein vivo IL-2 exposure, function similarly to PBL obtained from patients following IL-2, in that low-level LAK activity was significantly boosted by inclusion of IL-2 during the cytotoxic assay and the cells also responded with secondary-like kinetics to subsequent IL-2in vitro. The augmentation of the LAK effect was also dependent on the dose of IL-2 added during the 4-h51Cr-release cytotoxicity assay, with higher doses of IL-2 having a more pronounced effect. While continuous infusion of IL-2 induces a greater cytotoxic potential per milliliter of blood obtained from patients, the peak serum IL-2 levels attained are greater with bolus IL-2 infusions. These pharmacokinetic results, together with the IL-2 dose dependence of LAK activity generatedin vivo shown in this report, suggest that a combination of treatment with bolus IL-2 infusions superimposed on continuous IL-2 infusion may transiently expose IL-2 dependent LAK cells, activatedin vivo, to higher concentrations of IL-2, facilitating theirin vivo cytotoxic potential.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Atkins MB, Gould JA, Allegretta M, Li JJ, Dempsey RA, Rudders RA, Parkinson DR, Reichlin S, Mier J (1986) Phase I evaluation of recombinant IL-2 in patients with advanced malignant disease. J Clin Oncol 4: 1380

    Google Scholar 

  2. Bradley EC, Doyle M, deGroat S, Damle NK, Doyle LV, Rudolf AR, Issell B (1987) LAK inductionin vivo in patients treated with interleukin-2 may be necessary for tumor regression. Proc Am Assoc Cancer Res 28: 405

    Google Scholar 

  3. Ettinghausen SE, Moore JG, White DE, Platanias L, Young NS, Rosenberg SA (1987) Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. Blood 69: 1654

    Google Scholar 

  4. Hank JA, Kohler PC, Weil-Hillman G, Rosenthal N, Moore KH, Storer B, Minkoff D, Bradshaw J, Bechhofer R, Sondel PM (1988)In vivo induction of the lymphokine-activated killer (LAK) phenomenon: Interleukin-2 (IL-2)-dependent human non-MHC restricted cytotoxicity (NRC) generatedin vivo during administration of recombinant human IL-2. Cancer Res 48: 1965

    Google Scholar 

  5. Hefeneider SH, Conlon PJ, Henney CS, Gillis S (1983)In vivo interleukin-2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells. J Immunol 130: 222

    Google Scholar 

  6. Kohler PC, Hank JA, Moore KH, Storer B, Bechhofer R, Hong R, Sondel PM (1989) Phase I clinical trial of recombinant interleukin-2: a comparison of bolus and continuous intravenous infusion. Cancer Invest (in press)

  7. Krigel RL, Padavic-Shaller KA, Rudolph AR, Litwin S, Konrad M, Bradley EC, Comis RL (1988) A phase I study of recombinant interleukin-2 plus recombinant β-interferon. Cancer Res 48: 3875

    Google Scholar 

  8. Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CAY, Custer MC, Rosenberg SA (1985)In vivo administration of purified human interleukin-2. II. Half life, immunologic effects and expansion of peripheral lymphoid cellsin vivo with recombinant IL-2. J Immunol 135: 2865

    Google Scholar 

  9. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA (1986) High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: Responses, treatment related morbidity, and histologic findings. J Am Med Assoc 256: 3117

    Google Scholar 

  10. McMannis JD, Fisher RI, Creekmore SP, Braun DP, Harris JE, Ellis TM (1988)In vivo effects of recombinant IL-2. I. Isolation of circulating Leu 19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2. J Immunol 140: 1335

    Google Scholar 

  11. Mitchell MS, Kempf RA, Harel W, Shau H, Boswell WD, Lind S, Bradley EC (1988) Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma. J Clin Oncol 6: 409

    Google Scholar 

  12. Miyasaka N, Darnell B, Baron S, Talal N (1984) Interleukin-2 enhances natural killing of normal lymphocytes. Cell Immunol 84: 154

    Google Scholar 

  13. Phillips JH, Gemlo BT, Myers WW, Rayner AA, Lanier LL (1987)In vivo andin vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy. J Clin Oncol 5: 1933

    Google Scholar 

  14. Pross HF, Maroun JA (1984) The standardization of NK cell assays for use in studies of biological response modifiers. J Immunol Methods 68: 235–249

    Google Scholar 

  15. Sondel PM, Hank JA, Rosenthal N, Moore KH, Hong R, Storer B, Kohler PC (1987) Clinical testing of IL-2;in vivo administration of IL-2 induces IL-2 dependent non-MHC restricted cytotoxicity (NRC). In: Truitt RL, Gale RP, Bortin MM (eds) Cellular immunotherapy of cancer. Alan R. Liss, New York, pp 173–184

    Google Scholar 

  16. Sondel PM, Kohler PC, Hank JA, Moore KH, Rosenthal NS, Sosman JA, Bechhofer R, Storer B (1988) Recombinant interleukin-2 given by repetitive weekly cycles to patients with cancer: clinical and immunologic effects. Cancer Res 48: 2561

    Google Scholar 

  17. Sosman JA, Kohler PC, Hank JA, Moore KH, Bechhofer R, Storer B, Sondel PM (1988) Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity. J Natl Cancer Inst 80: 60

    Google Scholar 

  18. Sosman JA, Kohler PC, Hank JA, Moore KH, Bechhofer R, Storer B, Sondel PM (1988) Repetitive weekly cycles of interleukin-2 (IL-2): clinical and immunologic effects of dose, schedule and indomethacin. J Natl Cancer Inst 80: 1451

    Google Scholar 

  19. Svedersky LP, Shepard HM, Spencer SA, Shalaby MR, Palladino MA (1984) Augmentation of human natural cell mediated cytotoxicity by recombinant human interleukin-2. J Immunol 133: 713

    Google Scholar 

  20. Thompson JA, Peace DJ, Klarnet JP, Kern DE, Greenberg PD, Cheever MA (1986) Eradication of disseminated murine leukemia by treatment with high-dose interleukin-2. J Immunol 136: 3675

    Google Scholar 

  21. Rosenberg SA, Mulé JJ, Spies PJ, Reichert CM, Schwarz SL (1985) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-doses recombinant interleukin-2. J Exp Med 161: 1169

    Google Scholar 

  22. Rosenthal NS, Hank JA, Kohler PC, Minkoff DZ, Moore KH, Bechhofer R, Hong R, Storer B, Sondel PM (1988) Thein vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombbinant IL-2. J Biol Response Mod 7: 123

    Google Scholar 

  23. Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Levitt D, Fefer A (1988) Influence of dose and duration of interleukin-2 on toxicity and immunomodulation. J Clin Oncol 6: 669

    Google Scholar 

  24. Weil-Hillman G, Hank JA, Rosenthal NS, Sondel PM (1988) Transient decrease in IL-2 responsive lymphocytes 24 hours after initiation of continuous IL-2 infusion in cancer patients. J Biol Response Mod 7: 424

    Google Scholar 

  25. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RB (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Human Oncology, University of Wisconsin, Madison, Wisconsin, USA

    Jacquelyn A. Hank, Gilda Weil-Hillman, Jean E. Surfus, Jeffrey A. Sosman & Paul M. Sondel

  2. Department of Pediatrics, University of Wisconsin, Madison, Wisconsin, USA

    Paul M. Sondel

  3. Department of Genetics, University of Wisconsin, Madison, Wisconsin, USA

    Paul M. Sondel

Authors
  1. Jacquelyn A. Hank
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gilda Weil-Hillman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean E. Surfus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jeffrey A. Sosman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paul M. Sondel
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported by NIH contract NO1 CM-47669-02, NIH grants CA-32685, RR-031086, NO1 CM-47669-03, and American Cancer Society grant CH-237

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hank, J.A., Weil-Hillman, G., Surfus, J.E. et al. Addition of interleukin-2in vitro augments detection of lymphokine-activated killer activity generatedin vivo . Cancer Immunol Immunother 31, 53–59 (1990). https://doi.org/10.1007/BF01742496

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01742496

Keywords

Search

Navigation